Downregulation of major histocompatibility complex (MHC) class I expression is an important mechanism by which tumors evade classical T cell-dependent immune responses. Therefore, a system was designed to evaluate parameters for active immunization against MHC class Itumors. Mice were capable of rejecting a MHC class I-tumor challenge after immunization with an irradiated granulocyte/macrophage colony-stimulating factor (GM-CSF) transduced MHC class I-tumor vaccine. This response was critically dependent on CD4 + T cells and natural killer (NK) cells, but minimally on CD8 + T cells. A strong protective response against MHC class I + variants of the tumor could be elicited when mice were immunized with irradiated MHC class I + GM-CSF-secreting tumor cells. This response required CD4 + and CD8 + T cells, and in addition, elimination of NK cells resulted in outgrowth of tumors that had lost expression of at least one MHC class I gene. Finally, class I MHC expression on the vaccinating cells inhibited the response generated against a MHC class I-tumor challenge. These results demonstrate that the host is capable of being immunized against a tumor that has lost MHC class I expression and reveal conditions under which distinct effector cells play a role in the systemic antitumor immune response.
T
he immune system is capable of recognizing and responding to tumors via several effector mechanisms. Recent evidence demonstrates that tumor-specific CTL can be generated which recognize tumor antigens presented on the cell surface together with MHC class I molecules (1, 2) . Such neoantigens are peptides derived from endogenously synthesized proteins which are seen as foreign by the host, either as a consequence of mutations that arise during malignant transformation or tumor expression of gene products not normally expressed in adult tissues. The predicted consequence of such a T cell-mediated selective pressure is outgrowth of tumors that have lost expression of these antigens, or equivalently, loss of the class I MHC molecules themselves. Indeed, reports of diminished class I expression on clinically advanced tumors and metastases are consistent with this idea (3) (4) (5) . Likewise, in the majority of experimental models tested, introduction of MHC class I genes into MHC class F ~ tumor cells to increase their surface expression results in a decrease in in vivo tumorigenicity (6) (7) (8) (9) .
In contrast to T cell-mediated, MHC-restricted recognition of tumor, NK cells are known to be able to kill certain tumor cell lines in spite of the fact that they express little or no MHC class I antigen. The nature of the recognition molecules involved in NK-target cell interaction is not well understood, although emerging data support the hypothesis that one pathway of NK cell activation occurs as a consequence of encountering cells that have lost self-MHC expression (10) . Mechanistically, target expression of class I MHC would either mask the NK receptor ligand, precluding activation, or alternatively, NK cell engagement with target MHC would result in an inactivation signal. In vitro data demonstrate that many class I-, NK-sensitive targets are rendered resistant to lysis by restoring or increasing MHC class I expression (11) (12) (13) . This recognition appears to be at least partially haplotype specific, as expression of allogeneic class I molecules on the target still results in sensitivity to NK lysis. Recent studies of cloned human NK cell line allospecificity demonstrate that the trait of susceptibility to NK lysis is inherited in an autosomal recessive fashion and segregates with MHC haplotypes, compatible with the activation signal being the failure to encounter self-MHC (14, 15) . This pattern of NK activation does not appear to be restricted to tumor recognition, as NK cell-mediated bone marrow graft rejection has been shown to occur when an otherwise MHC-identical marrow graft lacks a single MHC locus of the recipient (16, 17) .
Seemingly at odds with the in vivo consequence of enhanced tumor MHC expression mentioned above, studies of several MHC class I-deficient tumors report rejection of small tumor inocula by syngeneic recipients, whereas the MHC dass I + wild-type counterparts are tumorigenic (12, 18, 19) . Similarly, in the B16 murine melanoma model, the ability to form lung metastases has been shown to be inversely related to the class I MHC expression on the tumor (20) . In these models, elimination of NK cells results in the loss of the response to MHC class I-tumors.
To examine the interplay of these distinct effector pathways in a single tumor system, we used a strategy of immunization with genetically modified tumor vaccines followed by live tumor challenge to dissect the role of these different effector cells in tumor rejection in vivo as a function of class I MHC expression.
Materiah and Methods
Tumor Cells. B78H1 cells were obtained from L. Graf, Jr.
(University of Illinois College of Dentistry, Chicago, IL; 21). The F10 subline of B16 mdanoma cells (22) was obtained from the National Institutes of Health Depository of Cells and Tissues. Cells were cultured in vitro in RPMI media, supplemented with 10% FCS, penicillin/streptomycin (50 U/ml), t-glutamine (2 raM), sodium pyruvate (1 raM), and nonessential amino acids (0.1 mM), and grown at 37~ 5% CO2. All cells were periodically tested for, and found to be free of mycoplasma contamination. Detection of MHC Class I mRNA. B78H1 and B16F10 were grown in vitro with or without the addition of recombinant mufine IFN-~/(100 U/ml for 3 d). Cell were trypsinized and washed in serum-free HBSS, and total cellular RNA was isohted from 107 cells that were denatured in the presence of guanidinium thiocyanate (23) . cDNA was prepared by reverse transcriptase reaction using standard procedures (24) . 1 gg of cDNA was amplified by PCR utilizing a 5' consensus primer for H-2D s and H-2K b (5'-CGC GAC GCT GCT GCG CAC AG-3'), and 3' primers specific for H-2D s (5'-TAC AAT CTC GGA GAG ACA TT-3') or H-2K b (5'-TAC AAT CTG GGA GAG ACA GA-3'). Amplification of dihydrofolate reductase message served as a positive control using the primers 5'-CTC AGG GCT GCG ATT TCG CGC CAA ACT and 3'-CTG GTA AAC AGA ACT GCG TCC GAC TAT C. Conformation of purity was performed after in vitro expansion, and as many as five sorts were required to obtain populations with homogeneous expression. GM-CSF production was achieved via retroviral transduction of the MHC variants with MFG GM-CSF as described (29) . All cellular constructs were expanded in vitro and aliquots frozen in liquid nitrogen before in vivo studies, enabling newly thawed reagents to be used in each experiment. GM-CSF Assays. GM-CSF production was quantified by collection of tumor supematant (2 x 10 s cells in 5 ml for 24 h) and assaying for support of the GM-CSF-dependent cell line NFS-60. Dilutions of supematant were transferred to 96-well microtiter plates containing 10,000 NFS-60 cells per well. After 48 h, [3H]thymidine (1 gCi/well) was added for 12 h after which incorporation was assessed with a cell harvester. Units of GM-CSF were calculated by comparison to a standard curve generated with recombinant GM-CSF. CTL Assay~ Spleens were removed from BALB/c and C57BL/6 mice and single cell suspensions were created by mechanical dissociation and passage over nylon mesh. Red cells were removed by Ficoll density centrifugation, and lymphocytes were washed and counted. BALB/c responder cells were plated in 24-well plates at 5 x 106 cells/well. B78HIDbK b cells or C57BL/6 splenocytes were added as stimulators after incubation with mitomycin C (50 gg/ml for 1 h at 37~ then three washes in RPMI-10% FCS). 10 U/m1 of recombinant murine Ib2 was added per well. After 5 d, SlCr-release assays were performed as described (30) using B78H1 or B78HIDbK s as targets.
In Vivo Protection Assays. Cells for injection were harvested from in vitro culture by trypsinization after limited expansion and washed three times in serum-free HBSS. GM-CSF-producing vaccine cells were irradiated (5,000 tad) before injection. All injections were in 0.1 ml given subcutaneously in the left (vaccine) or right (challenge) flank. All experiments included 10 mice per group, and each was repeated at least once. Mice were monitored twice weekly, and euthanized after the development of tumor.
In Vivo Antibody Depletions. In vivo antibody depletions were started 1 wk before vaccination, mAb GK1.5 (31) was used f~r CD4 depletions, mAb 2.43 (32) was used for CD8 depletions, and mAb PK136 (33) was used for NK depletion. Ammonium sulfate-purified ascites fluid (titered at >1:2,000 by staining of splenocytes on the FACS ~ was injected intraperitoneally (0.1 ml per mouse) every other day for the first week and once per week afterward. Depletion of lymphocyte subsets was assessed on the day of vaccination, the day of live tumor challenge, and weekly thereafter by flow cytometric analysis of spleen calls stained with 2.43 or GK1.5 followed by FITC-labeled goat antibody to rat IgG (Kirkegaard & Perry Labortories, Inc., Gaithersburg, MD) or PK136 followed by FITClabeled goat antibody to mouse IgG. For each time point of analysis, >99% depletion of the appropriate subset was achieved with normal levels of other subsets.
Results

B78H1 Does not Express MHC Class I Molecules.
The murine mdanoma B78H1 is an amdanotic done of the C57BL/6-derived tumor B16 (34) . B16 expresses low levels of MHC class I molecules, it is not truly MHC dass I-, and expres-sion can be significantly increased after exposure to IFN-3,. In contrast, B78H1 has been shown to express no detectable MHC class I antigen in vitro or after in vivo passage, and such expression is not inducible with IFN-7 (35) . The absence of surface expression of MHC class I is due to an absence of mRNA transcripts. RNA was isolated from B78H1 and B16F10 cultured with and without IFN-3'. cDNA was prepared by reverse transcriptase reaction, and PCR amplification was performed using H-2D b, H-2K b, or dihydrofolate reductase (DHFR)l-specific oligonucleotide primers. H-2D b and H-K b transcripts were evident from B16F10 but could not be detected from B78H1, whereas DHFR transcripts were detected in all samples ( Fig. 1) .
Creation of MHC Class I Variants. The C57BL/6 strain of mice from which these tumors originated expresses only two classical MHC class I loci, H-2D b and H-2K b. Three MHC class I + variants of B78H1 were created via transfection of the tumor with either the plasmid vector pMo/D b (containing a neomycin resistance gene and an H-2D b genomic segment), plasmid pKbT.8 (containing a neomycinresistance gene and an H-2K b cDNA), or both. Control transfections with the vectors minus the MHC genes were also performed. Transfectants were selected in the neomycin analog G418, and G418 resistant lines were prepared from more than 100 pooled clones of approximately equal size. Expanded polyclonal populations were stained with the mAb 28-14-8 (anti-Db), B8-24-3 (anti-Kb), or both, and sorted by flow cytometry. Analysis of the sorted transfectants revealed heterogeneously positive populations for the appropriate MHC antigens (Fig. 2) . Murine GM-CSF-producing vaccine was created by retroviral transduction of the parental class I-B78H1 and the H-2D b, H-2K b, and H-2DbK b variants using MFG-murine GM-CSF (10,000-20,000 U/2 x 10 s cells/ 24 h), as determined by in vitro bioassay on the GM-CSFdependent cell line NFS-60 (data not shown).
MHC Class I Expression In Viva
To determine the fidelity of MHC dass I expression in vivo, 106 cells of each MHC 1 Abbreviation used in this paper: DHFR, dihydrofolate reductase.
variants was injected subcutaneously in C57BL/6 mice. Animals were killed on day 11, and tumor samples were frozen in liquid nitrogen and prepared for immunohistochemical staining. Representative samples are shown (Fig. 3) and reveal no detectable MHC dass I expression on B78H1, whereas the D b and K b variants are positive for the correct locus in situ. This result not only confirms the expression of the transfected MHC molecules in vivo, but also suggests that unidentified host factors are not inducing MHC class I expression in the B78H1 wild-type tumor.
H-2b-speci.fic Allogeneic CTL Recognize B78H1 Class I + Variants but not B78H1 Wild Type. Although mAb staining confirms that the B78H1 MHC class I transfectants express the class I epitope to which the antibody binds, the relevant function that the MHC molecule must serve is the ability to present antigen to T cells. As a measure of this function, an allogeneic CTL assay was performed. BALB/c splenocytes (H-2d) were stimulated in vitro with mitomycin C-treated C57BL/6 (H-2b) splenocytes, or with B78H1DbK b. After 5 d in culture, the cells were harvested and tested for their ability to lyse Slchromium-labeled B78H1DbK b targets or B78H1 wild-type targets. Significant anti-B78H1DbK b CTL activity was detectable after incubation with either H-2b splenocytes or with B78H1DbK b itself, suggesting that allogeneic T cells were capable of recognizing the transfected MHC dass I molecules on B78HIDbK b (Fig. 4 A) . The majority of this in vitro activity was blocked by incubation with antibody to CD8. In contrast, the same allogeneic CTL had very little activity against the MHC class I-B78H1 wild-type targets, and none of this was blocked with anti-CD8 antibody (Fig. 4 B) , indicating that CD8 + T ceUs with specifidty for H-2D b and H-2K b do not recognize B78H1. Similarly, B78H1 wild type did not generate a class I-specific allogeneic CTL when used as a stimulator cell in vitro (data not shown).
In Vivo Immune Response to M H C Class I-Tumor. Previous studies of the systemic antitumor immune response induced by cytokine-producing tumor vaccines have revealed the dependence on MHC class I-restricted, CD8 + CTL (29, 30, 36) . Given that these effector cells are incapable of recognizing B78H1 in vitro, we tested the in vivo response against Figure I . Detection of class I MHC mRNA by RT-PCR. B78H1 and B16F10 cells were grown in the presence and absence of IFN-3, (100 U/ml) after which total cellular RNA was isolated and cDNA created by reverse transcriptase reaction. PCR amplification was performed on each sample using oligonucleotide primers specific for H-2Db, H-2K b, and dihydrofolate reductase. Reaction products were dectrophoresed on a 0.8% agarose gel and stained with ethidium bromide. Lanes: (I) BI6F10, (2) BI6F10 IFN-'y-treated, a B78H1 challenge (Fig. 5 A) . Remarkably, mice immunized with irradiated B78H1GM-CSF were largely protected against the MHC class I-tumor challenge at a distant site. Immunization with irradiated nontransduced B78H1 cells also produced some systemic protection against live B78H1 challenge but at a much lower level than GM-CSF transduced vaccine. To identify which call populations are involved in this response, in vivo lymphocyte subset depletion was performed with injections of mAb against CD4 + , CD8 +, or NKI.1 + cells initiated before the immunization with irradiated B78H1GM-CSF and maintained throughout the experiment (Fig. 5 B) . Subsequent challenge with B78H1 resulted in tumor formation in mice depleted of CD4 + T ceils and NKI.1 + ceils comparable to unimmunized controls, whereas the CD8 + T cell-depleted group was still significantly protected. The effect of CD8 + T cell depletion was small but was seen consistently over three experiments and may represent the elimination of a subset of NK cells that expresses CD8. Given the requirement for CD4 + T cells in the response to a MHC class I-tumor challenge, explanted tumor was stained for expression of MHC class II molecules ( (Fig. 7 B) . It is interesting to note that NK1 + cell depletion also resulted in the development of tumor outgrowth. Mice from this group were killed at the time of tumor detection and the tumors were explanted and stained for MHC class I expression (Fig.  8) . In all cases, tumors that developed in mice depleted of NK1 + cells lost expression of the dominant T call restric- 
Discussion
These experiments identify two distinct in vivo effector responses to a tumor challenge and illustrate conditions under which each predominates. The host is capable of successfully responding to tumor that has lost MHC class I expression even though this event eliminates the potential for tumorspecific CD8+T cell-mediated rejection. NK1 + cells are capable of responding to such an event, and under certain circumstances, they may complement the T cell response. Their function may be mediated by direct tumor lysis and/or the release of cytokines influencing the activation of other cells involved in the response. Whereas it has long been appreciated that NK cells can lyse MHC class I-tumor in vitro, and are involved in the in vivo rejection of such tumor in unprimed recipients, this is the first study to examine the con- sequences of tumor vaccine immunization on the activation of this cell type. The protective effect of a MHC dass Itumor vaccination against a MHC class I-challenge, as weU as the impairment of this response when the vaccinating ceUs express MHC class I, are consistent with a durable alteration in NK1 + cell function. This conclusion is somewhat at odds with the operational definition of NK cells as being "capable of lysing a variety of tumor ceUs in vitro without any known or deliberate sensitization" i.e., that resting cells are "naturally" functionally active. In vivo, however, viral infection or strong antigenic stimulation has been reported to lead to both activation of NK cells, and increase in NK cell number (37) . Alternatively, the priming of the host response to a MHC class I-challenge may be attributable to the level of CD4 + T cell help generated. In the GM-CSF tumor vaccine system, the central role of CD4 + Th cells may relate to the recruitment of "professional" APCs to the vaccine site which process and present tumor antigen on MHC class II molecules to CD4 + Th cells (29) . The activation of tumor-specific CD8 + CTL whose TCRs have first been engaged by the appropriate antigen-MHC complex is dependent upon the local secretion of lymphokines such as IL-2 which is the hallmark of CD4 + Th function. That most CTL responses require Th cells has long been appreciated (38) (39) (40) (41) . In contrast, this relationship to CD4 § Th activation has not been previously reported for NK cell function, although both in vitro and in vivo data suggest that NK cell activation is enhanced by IL-2 and IFN-7 (42, 43) . Our results suggest that CD4 + Th cell/NK cell interdependence may result in an additional degree of target specificity, as primed antigen-specific CD4 + Th cells would only release cytokines after recognition of the appropriate antigen presented on MHC class II of APCs in the region of a tumor deposit. It is also possible that CD4 + T cells are functioning as cytotoxic effector calls, although in this system, the tumor has not been found to express MHC class II in vivo.
The in vivo protection experiments were also performed using irradiated, non-GM-CSF-secreting tumor cells as vaccine. These experiments resulted in a similar pattern of protection to that reported for the GM-CSF transduced tumor vaccine, although the magnitude of the responses was significantly diminished. Thus it appears that the influence of MHC class I expression on the nature of the ensuing antitumor response is not dependent on GM-CSF, although in both the response to MHC class I positive and negative tumor, the total tumor burden successfully rejected is increased by the paracrine expression of this cytokine.
The negative effect of tumor vaccine MHC class I expression on the subsequent response to class I-challenge suggests that such an encounter with tumor vaccine either fails to activate NK cells, or directly inhibits them. This observation is consistent with a pattern of NK cell recognition first described over 30 yr ago and termed hybrid resistance (for reviews see references 44 and 45) . Lethally irradiated hybrid mice heterozygous at the MHC gene complex can reject bone marrow grafts from a homozygous parental donor. Host NK calls have been found to mediate this rejection (46) . Immunogenetic analysis has revealed that the determinants for hybrid resistance map to the MHC between H-2S (complement) and H-2D (47) . The nature of the NK cell recognition event remains controversial. The possibility of recessive inheritance of the antigens recognized by the F1 recipient on the parental graft has led to a search for gene products encoded in the H-2 region that can explain the observed pattern of graft rejection (hybrid histocompatibility antigens) (48) . An alternate explanation suggests that NK ceils are inactivated upon encountering self-MHC (possibly plus peptide) on a potential target, the failure of this event leading to lysis of the target. This "missing self' hypothesis (49) was supported by the ability of mice transgenic for an allogeneic class I MHC molecule (H-2D d) to reject an otherwise geneticaUy identical nontransgenic bone marrow but not marrow expressing H-2D a, formally demonstrating that expression of the class I MHC molecule itself can result in graft survival, whereas its absence can be recognized by the NK cells of the recipient leading to rejection (16) . In our model, similar mechanisms may account for the inhibitory effect of MHC class I + tumor on the subsequent NK cell-mediated response to MHC class I-tumor.
One implication of these findings is that in a heterogeneous tumor burden where loss of MHC class I antigens has occurred in some fraction of the tumor, the CD8 + T cell response is likely to be inadequate, and strategies of active immunotherapy must attempt to recruit alternate cytolytic effector ceils such as NK ceils which may facilitate tumor rejection. The use of class I-vaccinating cells as one component of the therapy may be effective in this setting. More generally, such an immunotherapeutic approach must include the consideration of a variety of responding cell populations and the conditions which affect the ability of each to contribute to a successful host response.
